Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Vascular Closure Device Market Size & Share 2026-2035
Report ID: GMI1967
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Vascular Closure Device Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Vascular Closure Device Market Size
The vascular closure device market was valued at USD 1.85 billion in 2025, is projected to reach USD 1.95 billion in 2026, and is expected to expand at a 5.4% CAGR (2026–2035), reaching USD 3.12 billion by 2035.
Vascular Closure Device Market Key Takeaways
Market Leader: Abbott Vascular led with over 32% market share in 2025.
Leading Players: Top 5 players in this market include Abbott Vascular, Terumo, Haemonetics, Cordis, Teleflex, which collectively held a market share of 74% in 2025.
The vascular closure device market is evolving with the mix of percutaneous procedures rather than with catheterization volume alone. Demand is increasingly shaped by the access-management requirements of structural heart and electrophysiology workflows, the migration of selected procedures into ambulatory settings, and the clinical value placed on dependable hemostasis, workflow efficiency, and complication avoidance.
GMI Analyst View
Our consultations with senior procurement executives and leading interventional cardiology stakeholders across key markets indicate that the global vascular closure device market generated approximately USD 1.70 billion in 2024, underscoring the sustained momentum in procedure volumes and device adoption that underpins GMI's forward projections for the 2026–2035 forecast period.
Vascular Closure Device Market Trends, Growth Drivers & GMI Forecast Outlook
Structural heart interventions, ambulatory cardiac care, and the expansion of interventional capacity are changing the market's demand profile. The forecast depends on manufacturers' ability to provide clinically dependable closure across large-bore, radial, and venous access while navigating training, evidence, and regulatory requirements.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Large-bore structural interventions make access-site management integral to procedure planning. In these settings, active closure systems are evaluated not merely on deployment speed, but on their ability to support predictable post-procedure recovery and preserve cath-lab throughput. This favors platforms with clinical familiarity, broad sheath compatibility, and established operator training pathways.
Cardiovascular care capacity is also broadening in markets where catheterization infrastructure is still developing. Manufacturers that pair distribution with physician education, local regulatory execution, and product configurations suited to variable site capabilities are better positioned to convert procedural expansion into recurring device demand.
The expansion of cardiac coverage in ambulatory surgical centers changes the purchasing environment for closure devices. Procurement increasingly emphasizes reliable performance in leaner operational settings, where shorter recovery pathways and standardized protocols can have an outsized effect on facility economics. The policy shift supports a distinct commercial opportunity for products designed around ambulatory workflow requirements.[3]
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Clinical confidence remains a central adoption constraint because access-site outcomes depend on both device performance and operator technique. Hospitals and ambulatory providers therefore tend to favor suppliers that can support standardized closure protocols, hands-on education, and post-market evidence generation. These requirements can lengthen conversion cycles for newer platforms, particularly outside high-volume centers.
Incomplete deployment has commercial consequences beyond the immediate procedure. Re-intervention risk, recovery delays, and institutional scrutiny increase the value of systems that are trusted across a broad range of operators and access profiles. This dynamic supports premium positioning for established active platforms while raising the evidence threshold for lower-cost alternatives and novel entrants.
Regulatory pathways add a supply-side constraint. Novel closure architectures must satisfy demanding clinical and safety expectations before entering major markets, which can delay competitive launches even where a technology addresses a meaningful unmet need. The resulting barrier rewards incumbents with mature regulatory portfolios but also makes differentiated clinical evidence a strategic requirement for innovators.
GMI Analyst View
We see the market dividing into two complementary demand environments: high-acuity structural programs that prioritize performance assurance and ambulatory settings that prioritize repeatable workflow efficiency. Suppliers that can address both without compromising clinical credibility should be better insulated from shifts in procedure location and product mix.
Vascular Closure Device Market Segment Analysis
By Product Type
Active VCDs held a 65.0% share of the vascular closure device market in 2025 and are projected to generate USD 2.16 billion by 2035. Their position reflects the clinical demands of femoral access management, particularly where operators require controlled closure performance across complex arterial procedures.
Passive VCDs generated USD 646 million in 2025 and are expected to represent a 30.8% share by 2035. Compression-based systems retain a practical role in transradial workflows, lower-acuity procedures, and care settings where procedural economics or clinical preference does not support routine use of active closure.
Collagen plug devices generated USD 369 million in 2025 and are projected to account for an 18.3% share by 2035. Their established role in conventional femoral access supports continued adoption where rapid deployment and familiar workflow integration matter, even as higher-acuity cases increasingly favor other active architectures.
Suture-mediated systems held a 17.0% share in 2025 and are projected to reach USD 463 million by 2035. Their relevance is closely linked to large-bore arterial management, where secure vessel-wall apposition and operator confidence carry greater weight than the simplicity offered by compression-oriented alternatives.
Large-bore VCDs generated USD 129 million in 2025 and are expected to expand at a 10.3% CAGR (2026–2035). Growth is tied to the rising procedural importance of structural heart interventions, which require closure systems capable of managing larger sheath profiles and demanding recovery pathways.
Venous/EP VCDs are projected to generate USD 331 million by 2035 and expand at an 8.4% CAGR (2026–2035). The category benefits from the increasing intensity of electrophysiology activity and the need for dedicated closure approaches in venous workflows that differ materially from conventional arterial catheterization.
Other active VCDs accounted for a 13.0% share in 2025 and are projected to reach USD 451 million by 2035. This group captures the commercial potential of alternative mechanisms and materials that target access scenarios where established plug and suture systems may not offer an optimal procedural fit.
Radial compression devices generated USD 369 million in 2025 and are expected to represent a 17.5% share by 2035. Their outlook is underpinned by the continued use of transradial approaches, where accessible, reproducible hemostasis remains central to efficient recovery and patient turnover.
Femoral compression systems held a 15.0% share in 2025 and are projected to generate USD 417 million by 2035. These products remain relevant where manual compression is clinically acceptable, cost discipline is pronounced, or active closure is not selected for the procedure.
By End User
Hospitals held a 72.0% share of the vascular closure device market in 2025 and are projected to generate USD 2.10 billion by 2035. Their scale reflects the concentration of complex catheterization, structural heart, and electrophysiology procedures in facilities with specialist teams, formal closure protocols, and broad formulary infrastructure.
Ambulatory surgical centers generated USD 406 million in 2025 and are expected to expand at a 7.6% CAGR (2026–2035). This channel is gaining importance as selected cardiac procedures move to outpatient settings, creating demand for products that balance procedural reliability with cost-aware purchasing and streamlined recovery operations.
Specialty clinics / EP centers held a 6.0% share in 2025 and are projected to generate USD 185 million by 2035. Their demand profile is shaped by dedicated rhythm-management workflows, where frequent venous access and high procedure turnover create a defined use case for specialized closure solutions.
By Access Site
Femoral arterial access accounted for a 57.0% share of the vascular closure device market in 2025 and is expected to represent a 51.3% share by 2035. Although alternative access routes are expanding, femoral access remains essential for many structural heart and peripheral interventions that require larger-bore entry.
Radial arterial access VCDs generated USD 554 million in 2025 and are projected to reach USD 1.04 billion by 2035. The category is supported by the operational advantages of transradial catheterization and the sustained need for effective wrist-based hemostasis in routine coronary workflows.
Venous access VCDs are projected to generate USD 335 million by 2035 and expand at an 8.5% CAGR (2026–2035). Their momentum reflects the increased procedural relevance of electrophysiology and structural interventions that use large-bore venous access and benefit from more specialized closure management.
GMI Analyst View
We expect product differentiation within active closure to become more consequential than the traditional active-versus-passive framing. Large-bore and venous applications require purpose-built clinical capabilities, so portfolio breadth, operator support, and evidence across multiple access profiles will increasingly determine suppliers' ability to defend share.
Vascular Closure Device Market Regional Analysis
North America Vascular Closure Device Market Analysis
The vascular closure device market in North America held a 41.0% share in 2025 and is projected to generate USD 1.21 billion by 2035. Deep cath-lab infrastructure, broad structural heart adoption, and an established ambulatory transition sustain a premium product mix and make clinical evidence a critical basis for purchasing decisions.
U.S. The U.S. generated USD 681 million in 2025 and is projected to reach USD 1.09 billion by 2035. High procedural intensity and mature structural-heart programs support demand for active and large-bore platforms, while reimbursement and hospital formulary practices continue to shape product adoption.
Canada Canada represented 10.0% of North American revenue in 2025 and is projected to generate USD 120 million by 2035. Provincial procurement structures favor suppliers that can demonstrate both clinical performance and cost-effectiveness, often resulting in deliberate formulary adoption cycles.
Europe Vascular Closure Device Market Analysis
Europe generated USD 480 million in 2025 and is projected to account for a 23.8% share by 2035. The region combines sophisticated intervention programs with heterogeneous reimbursement and procurement systems, placing a premium on clinical documentation, value demonstration, and regulatory readiness.
Germany Germany generated USD 101 million in 2025 and is projected to represent 21.1% of European revenue by 2035. Its dense catheterization network and role in European device adoption make it an important market for suppliers seeking to establish premium-platform credibility.
France France represented 17.9% of European revenue in 2025 and is projected to generate USD 134 million by 2035. Adoption is influenced by the concentration of cardiac intervention in major centers and by evidence-led procurement processes that can favor established clinical data.
UK The UK generated USD 72 million in 2025 and is projected to reach USD 112 million by 2035. Centralized purchasing and health-economic evaluation elevate the importance of demonstrating workflow and outcomes value alongside device performance.
Italy Italy generated USD 67 million in 2025 and is projected to account for 14.0% of European revenue by 2035. The country's active electrophysiology community creates a differentiated opportunity for venous and EP-focused closure platforms.
Spain Spain represented 10.0% of European revenue in 2025 and is projected to generate USD 75 million by 2035. Centralized tender environments reinforce the advantage of suppliers that pair competitive pricing with comprehensive safety and regulatory documentation.
Asia Pacific Vascular Closure Device Market Analysis
Asia Pacific is projected to generate USD 848 million by 2035 and expand at a 7.2% CAGR (2026–2035). The region's growth reflects expanding interventional infrastructure, rising procedural capacity, and the strategic importance of localized training, market access, and distribution capabilities.
China China represented 38.9% of Asia Pacific revenue in 2025 and is projected to generate USD 356 million by 2035. Expanding cath-lab capacity supports demand growth, while volume-based procurement intensifies pricing discipline and increases the importance of cost-effective commercial models.
Japan Japan generated USD 105 million in 2025 and is projected to account for 22.4% of Asia Pacific revenue by 2035. Its mature cardiology infrastructure supports demand for clinically validated products, although reimbursement discipline can limit pricing flexibility for new introductions.
India India is projected to expand at a 10.0% CAGR (2026–2035) and generate USD 163 million by 2035. Broadening catheterization capacity, private-hospital investment, and growing access to trained interventional specialists create a substantial opening for suppliers that invest early in clinical education and channel development.
South Korea South Korea generated USD 55 million in 2025 and is projected to represent 10.7% of Asia Pacific revenue by 2035. Advanced clinical infrastructure and an innovation-oriented provider base make the country an important early-adoption market for differentiated closure technologies.
Latin America Vascular Closure Device Market Analysis
Latin America is projected to generate USD 168 million by 2035 and expand at a 6.2% CAGR (2026–2035). Demand is concentrated in markets where private hospital investment and selective public-sector procurement are expanding access to advanced cardiac intervention.
Brazil Brazil generated USD 37 million in 2025 and is projected to reach USD 64 million by 2035. The divide between private and public providers produces distinct purchasing behavior, with premium active platforms gaining traction in private networks while cost-sensitive settings retain greater reliance on compression-based options.
Mexico Mexico represented 30.4% of Latin American revenue in 2025 and is projected to generate USD 50 million by 2035. High-acuity cardiac activity in major urban private networks gives the market influence beyond its size and makes it a practical entry point for broader regional commercialization.
Middle East & Africa Vascular Closure Device Market Analysis
Middle East & Africa generated USD 92 million in 2025 and is projected to reach USD 157 million by 2035. Growth is concentrated in Gulf markets investing in cardiac centers and specialist capacity, while broader African demand remains dependent on infrastructure and public-procurement development.
Saudi Arabia Saudi Arabia generated USD 26 million in 2025 and is projected to reach USD 44 million by 2035. Investment in cardiac capacity and specialist workforce development supports demand for structural heart and electrophysiology-adjacent closure technologies.
UAE The UAE represented 18.5% of Middle East & Africa revenue in 2025 and is projected to generate USD 31 million by 2035. Its concentration of premium private hospitals and role as a regional distribution hub make it a strategic commercial foothold for suppliers entering the wider Middle East.
South Africa South Africa generated USD 11 million in 2025 and is projected to reach USD 17 million by 2035. Demand is concentrated in private hospital networks, while wider adoption remains tied to the pace and direction of public-sector healthcare reform.
GMI Analyst View
We believe geographic success will depend on more than market entry. Suppliers that establish clinical training, regulatory readiness, and durable local partnerships before procedure volumes mature in emerging markets can shape purchasing norms; late entrants may face entrenched platform preferences and difficult channel economics.
Vascular Closure Device Market Share & Competitive Landscape
The vascular closure devices market exhibits a moderately concentrated competitive structure, with Abbott Vascular, Terumo, Haemonetics, Cordis, and Teleflex collectively accounting for approximately 74.0% of global market revenue in 2025. Market competition is driven by the strength of clinical evidence, physician adoption and familiarity, product performance across arterial and venous access sites, regulatory approvals, and the ability to support hospitals and ambulatory care providers with comprehensive vascular access management solutions.
Other market participants, including Medtronic, Ensite Vascular, Meril Life Sciences, Merit Medical, and Rex Medical, compete through specialized vascular closure technologies, regional market presence, and targeted clinical applications. Emerging companies such as Transluminal Technologies, Tricol Biomedical, TZ Medical, Vasorum, and Vivasure Medical are focused on innovative closure mechanisms and advanced biomaterial technologies designed to address evolving requirements in large-bore arterial and venous access procedures. As procedure volumes continue to increase, competition is increasingly centered on clinical outcomes, ease of deployment, operator confidence, and support for complex cardiovascular interventions rather than device functionality alone.
Recent Industry Developments
In August 2024, Haemonetics announced the full market release of VASCADE MVP XL, extending its closure portfolio to larger-bore access profiles and strengthening its relevance in procedures requiring expanded sheath compatibility.[5]
In March 2025, Vasorum received FDA approval for its Celt ACD PLUS vascular closure device, advancing the company's commercial position in femoral arterial closure with an extravascular architecture.[6]
In June 2025, Vivasure Medical submitted a premarket approval application for PerQseal Elite and received CE mark approval for an expanded venous indication in Europe, marking parallel regulatory progress for its fully absorbable closure platform.[7]
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →